Company / Operating Income
Viking Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$393.3M
FY2025
5-year range
-$393.3M / -$42.7M
FY2021-FY2025
Trend
-160.6%
vs FY2024
Sector context
#180 of 204
Health Care
What the data says
Viking Therapeutics, Inc.'s operating income of -$393M is lower than 88% of companies in the Health Care sector (FY2025). Declined from -$56M to -$393M over the past 2 years.
Based on SEC 10-K filings.
-$393M in FY2025.
Declined from -$56M to -$393M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 204This company -$393.3M Sector average $107.7M
▼
-465.2% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 160.6% year-over-year.
- Ranks #180 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$393.3M | -160.6% |
| FY2024 | -$150.9M | -171.0% |
| FY2023 | -$55.7M | +0.0% |
| FY2022 | -$55.7M | -30.5% |
| FY2021 | -$42.7M | -30.5% |
| FY2020 | -$32.7M | -24.9% |
| FY2019 | -$26.2M | -37.2% |
| FY2018 | -$19.1M | +0.0% |
| FY2017 | -$19.1M | -59.0% |
| FY2016 | -$12.0M | +48.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026